Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Wait a Little Longer, Ligand

It's becoming painfully predictable at this point, but the latest setback for GlaxoSmithKline (NYSE: GSK  ) and partner Ligand Pharmaceuticals (Nasdaq: LGND  ) still isn't ideal for either. On Friday, the duo announced that the FDA delayed the review of their blood-disorder drug Promacta by as much as three months.

By postponing its review of romiplostim, a rival idiopathic thrombocytopenic purpura (ITP) compound from Amgen (Nasdaq: AMGN  ) , several months ago, the FDA increased its odds of similarly delaying a review of Promacta's New Drug Application. The FDA is now set to rule on Amgen's long-term use ITP drug on July 23.

If the agency takes the full three extra months to make an approval decision on Promacta, its review date should be on or around Sept. 19. Don't assume that date's set in stone; other drugmakers like Cardiome (Nasdaq: CRME  ) and CV Therapeutics (Nasdaq: CVTX  ) have proven otherwise.

Ligand needs Promacta approved to juice up its revenue. Its only currently marketed drug is the pain compound Avinza, sold by partner King Pharmaceuticals (NYSE: KG  ) . It receives royalties on Avinza, and if approved, it would receive a 5% to 10% royalty rate on Glaxo's sales of Promacta.

Last month, Promacta was subjected to a relatively positive FDA advisory panel hearing. Although the panel abstained from voting on whether to recommend delaying approval pending more data, it did vote 16-0 that the drug "demonstrated a favorable risk-benefit profile" for short-term ITP treatment.

Promacta's delay is just one of the FDA's many pushed-back review dates this year; aside from some biologics, nearly every new drug has faced postponements. Investors should probably assume at least an additional three-month review period for any New Drug Applications submitted to the agency, given this current harsh regulatory environment.

CV Therapeutics is an active pick of our Rule Breakers newsletter. You can check out all our other recommendations, and get full access to our message boards and exclusive content, with a 30-day free trial.

Fool contributor Brian Lawler does not own shares of any company mentioned in this article. GlaxoSmithKline is an active Income Investor pick. The Fool has an A+ disclosure policy.

Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 670435, ~/Articles/ArticleHandler.aspx, 10/27/2016 3:32:08 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 6 hours ago Sponsored by:
DOW 18,199.33 30.06 0.17%
S&P 500 2,139.43 -3.73 -0.17%
NASD 5,250.27 -33.13 -0.63%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/26/2016 4:02 PM
GSK $40.34 Up +0.02 +0.05%
GlaxoSmithKline CAPS Rating: ***
LGND $95.15 Up +1.86 +1.99%
Ligand Pharmaceuti… CAPS Rating: ***
AMGN $158.99 Up +1.10 +0.69%
Amgen CAPS Rating: ****
CRME $2.90 Up +0.04 +1.40%
Cardiome Pharma CAPS Rating: *
CVTX.DL $20.01 Down +0.00 +0.00%
CV Therapeutics CAPS Rating: **
KG.DL2 $0.00 Down +0.00 +0.00%
King Pharmaceutica… CAPS Rating: **